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To the Editor
Since the onset of the current coronavirus 
disease 2019 (COVID-19) pandemic, there have 
been attempts to identify medications for severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). As there have been no antivirals available 
for the treatment of this disease, repurposing of 
drugs has started and various classes of drugs 
are being tried. Some of the candidate drugs 
include remdesivir (recently approved by Food 
and Drug Administration), ivermectin, and inter-
feron b-1b. There is emerging evidence regarding 
the efficacy of these drugs; however, no definite 
conclusions are available. A recent study by 
Shi et al. reported results about the efficacy of 
antiviral therapies in patients with coronavirus 
disease 2019 (COVID-19) in China and found no 
significant impact on improvement [1]. Similar 
results were reported in a recently published 
randomized controlled trial (RCT) about the 
use of interferon b-1a in patients with severe 
coronavirus disease 2019 (COVID-19) and found 
no significant difference in the time to clinical 
response in the experimental arm as compared 
to the control arm [2]. However, there are a few 
aspects regarding the timing of the initiation of 
antivirals which require discussion. In both of 
these studies, the authors have not reported the 
timing of initiation of antiviral therapy, which is 
crucial to patient outcomes. We all understand 
that the host’s immune response plays a crucial 
role in the prevention as well as containment of 
any infection; however, when an antiviral agent 
is sought for patients with disease or for patients 
who are at risk of severe disease, it should be done 
in a timely manner [3]. COVID-19 has an initial 
virological phase which leads the patients into 
a host inflammatory response phase where they 
tend to develop a cytokine storm [4]. Based on the 
report by Wölfel et al. [5] which states that the vi-
rus cannot be isolated beyond day 8, it is also like-
ly that antivirals may not be efficacious beyond 
this time. Thus, it would be best to use antiviral 
medications relatively early in the illness and an-
ti-inflammatory drugs later. Using antiviral drugs 
later in the disease course may add to the adverse 
effects rather than yielding clinical benefits. In 
the study by Effat et al. [2], the mean (standard 
deviation, SD) duration of starting treatment in 
the interferon arm was 11.7 (5.71) days. This late 
initiation of antiviral therapy may be the reason 
behind no difference in time to clinical response, 
which was the primary endpoint. However, there 
was a difference with respect to the percentage of 
patients being discharged by day 14, favouring the 
interferon group. Such a result may be owed to 
the properties of interferon, which endorses more 
than just an antiviral mechanism (i.e. decreasing 
vascular leakage and inflammatory biomarkers 
like IL-6) [6, 7]. They also reported that starting 
interferon treatment early in the course of the 
disease showed mortality benefit (odds ratio, 13.5; 
95% confidence interval 1.5 to 118) which further 
emphasizes the importance of early initiation of 
therapy [2].
Table 1 enlists some noteworthy trials in 
COVID-19 regarding the use of antiviral med-
ications and timing of treatment initiation for 
the outcome reported. Remdesivir showed no 
benefit when treatment was started after ten days 
of illness. Instead, it was associated with higher 
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mortality than the control arm [8]. However, when 
used within ten days, it tended to show benefits 
in other trials [9, 10]. Most other trials tend to 
start antivirals late and have reported no clinical 
benefits with their use. 
This brings us to essential questions of wheth-
er these drugs, if initiated early, can lead to clinical 
benefits, and whether or not these negative trials 
are giving us a false portrayal of their efficacy. 
Based on the available evidence, we suggest that 
antivirals should be initiated within the first ten 
days of illness, especially in research settings. In 
this COVID era, with the limited therapeutic op-
tions available to physicians, the appropriate and 
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Table 1. List of studies with use of antivirals and outcomes reported
Author Drug Number of 
patients
Study design Day of initiation 
of treatment from 
symptom onset
Outcome in comparison 
to control or standard of care
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Beigel et al. [10] Remdesivir 1063 RCT 9 The remdesivir group had a shorter time to 
recovery (median, 11 days, as compared 
with 15 days; rate ratio for recovery, 1.32; 
95% CI 1.12 to 1.55; p < 0.001)
Cao et al. [11] Lopinavir- 
ritonavir
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Hung et al. [12] Interferon beta-1b, 
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[IQR 5–11]) than the control group (12 days 
[8–15]; HR 4·37 [95% CI 1.86–10.24], p = 
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Clinical improvement was better in the com-
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Zhou et al. [7] Interferon alpha 77 Non rando-
mized
8 Significant accelerated viral clearance (p = 
0.002), and reduced circulating levels of IL-6 
(p = 5.7 × 10−10) and CRP (p = 0.002)
CI — confidence interval; CRP — C-reactive protein; HR — hazard ratio; Il-6 — interleukine 6; IQR — interquartile range; OR — odds ratio; RCT — randomized clinical trial
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